Scholarlink

Background <p>Immune checkpoint inhibitors (ICI) are pivotal in cancer treatment. However, not all patients are responsive to current ICI therapies, and new targets are needed. Thus, the HLA-G/ILT2 pathway emerges as one such potential ICI. The present study aimed to analyze the implications of this pathway in cytotoxic T cells from patients with gastric adenocarcinoma.</p> Methods <p>Peripheral blood mononuclear cells (PBMCs), and tissue infiltrating lymphocytes were obtained from 16 patients with gastric adenocarcinoma. PBMCs from 17 healthy subjects were used as controls. Cells were subjected to flow cytometry on the one hand and stimulation (assessed by IFNγ production) and proliferation assays, in the presence or absence of HLA-G, on the other.</p> Results <p>Despite lower CD3 + counts (<i>p</i> = 0.0036), CD3 + CD8 + ILT2 + (ILT2 + Tc) cells are overrepresented in patients, compared to control subjects (<i>p</i> &lt; 0.0001). These ILT2 + Tc exhibit enhanced anti T-cell receptor (TCR)-stimulated IFNγ production, compared to its counterparts ILT2– Tc (<i>p</i> = 0.0039), which was impaired by the presence of HLA-G (<i>p</i> = 0.0002). Proliferative responses of Tc were significantly reduced by HLA-G (<i>p</i> &lt; 0.0001) after 5&#xa0;days of stimulation. Finally, simultaneously PD1 and ILT2 staining revealed differential expression patterns between patients.</p> Conclusions <p>CD8 + T cells expressing ILT2 are overrepresented in patients with gastric adenocarcinoma, independent of PD-1 expression, and appear particularly susceptible to functional suppression in the presence of HLA-G–positive tumors. These findings highlight the immunomodulatory role of HLA-G in the tumor microenvironment and support its relevance as a potential target for personalized immunotherapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hampered CD8 + ILT2 + T cell activation by HLA-G suggests a new immune checkpoint in gastric adenocarcinoma

  • 期刊论文

  • 发表日期：

    2025年12月4日

查看全文
  • Christian Vaquero-Yuste,
  • Ignacio Juarez,
  • Marta Molina-Alejandre,
  • Alberto Gutiérrez-Calvo,
  • Adela López-García,
  • Inmaculada Lasa,
  • Remedios Gómez,
  • Antonio Arnaiz-Villena,
  • José Manuel Martín-Villa

摘要

Background

Immune checkpoint inhibitors (ICI) are pivotal in cancer treatment. However, not all patients are responsive to current ICI therapies, and new targets are needed. Thus, the HLA-G/ILT2 pathway emerges as one such potential ICI. The present study aimed to analyze the implications of this pathway in cytotoxic T cells from patients with gastric adenocarcinoma.

Methods

Peripheral blood mononuclear cells (PBMCs), and tissue infiltrating lymphocytes were obtained from 16 patients with gastric adenocarcinoma. PBMCs from 17 healthy subjects were used as controls. Cells were subjected to flow cytometry on the one hand and stimulation (assessed by IFNγ production) and proliferation assays, in the presence or absence of HLA-G, on the other.

Results

Despite lower CD3 + counts (p = 0.0036), CD3 + CD8 + ILT2 + (ILT2 + Tc) cells are overrepresented in patients, compared to control subjects (p < 0.0001). These ILT2 + Tc exhibit enhanced anti T-cell receptor (TCR)-stimulated IFNγ production, compared to its counterparts ILT2– Tc (p = 0.0039), which was impaired by the presence of HLA-G (p = 0.0002). Proliferative responses of Tc were significantly reduced by HLA-G (p < 0.0001) after 5 days of stimulation. Finally, simultaneously PD1 and ILT2 staining revealed differential expression patterns between patients.

Conclusions

CD8 + T cells expressing ILT2 are overrepresented in patients with gastric adenocarcinoma, independent of PD-1 expression, and appear particularly susceptible to functional suppression in the presence of HLA-G–positive tumors. These findings highlight the immunomodulatory role of HLA-G in the tumor microenvironment and support its relevance as a potential target for personalized immunotherapeutic strategies.